Terns Pharmaceuticals (NASDAQ:TERN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Terns Pharmaceuticals (NASDAQ:TERN) to a sell rating in a research note released on Saturday morning.

Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “neutral” rating and set a $53.00 target price (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th. Citizens Jmp cut shares of Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a report on Thursday, March 26th. TD Cowen cut shares of Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 target price for the company. in a report on Thursday, March 26th. Oppenheimer reissued a “market perform” rating and set a $58.00 target price on shares of Terns Pharmaceuticals in a report on Monday, April 27th. Finally, Leerink Partners cut shares of Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 8th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $55.14.

Terns Pharmaceuticals Stock Performance

NASDAQ TERN opened at $52.95 on Friday. The company has a fifty day simple moving average of $50.15 and a two-hundred day simple moving average of $38.53. The stock has a market cap of $6.12 billion, a P/E ratio of -51.41 and a beta of -0.37. Terns Pharmaceuticals has a 12-month low of $2.65 and a 12-month high of $53.19.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.06. As a group, sell-side analysts forecast that Terns Pharmaceuticals will post -1.22 earnings per share for the current year.

Insider Buying and Selling at Terns Pharmaceuticals

In related news, insider Emil Kuriakose sold 942 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the sale, the insider owned 105,673 shares in the company, valued at approximately $5,574,250.75. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. This trade represents a 4.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 30,108 shares of company stock worth $1,302,370. 1.50% of the stock is owned by company insiders.

Institutional Trading of Terns Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Morgan Stanley grew its position in shares of Terns Pharmaceuticals by 4.7% in the fourth quarter. Morgan Stanley now owns 7,945,608 shares of the company’s stock valued at $321,003,000 after purchasing an additional 356,513 shares during the period. Commodore Capital LP acquired a new stake in shares of Terns Pharmaceuticals in the third quarter valued at about $42,807,000. Adage Capital Partners GP L.L.C. grew its position in shares of Terns Pharmaceuticals by 40.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company’s stock valued at $224,220,000 after purchasing an additional 1,611,000 shares during the period. Vanguard Group Inc. grew its position in shares of Terns Pharmaceuticals by 21.1% in the fourth quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company’s stock valued at $223,167,000 after purchasing an additional 964,031 shares during the period. Finally, Vestal Point Capital LP acquired a new stake in shares of Terns Pharmaceuticals in the fourth quarter valued at about $181,800,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical?stage biopharmaceutical company focused on developing oral small?molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.